Literature DB >> 25540270

Survey of immunological features of the alpha-like proteins of Streptococcus agalactiae.

Johan A Maeland1, Jan E Afset2, Randi V Lyng3, Andreas Radtke4.   

Abstract

Nearly all Streptococcus agalactiae (group B streptococcus [GBS]) strains express a protein which belongs to the so-called alpha-like proteins (Alps), of which Cα, Alp1, Alp2, Alp3, Rib, and Alp4 are known to occur in GBS. The Alps are chimeras which form mosaic structures on the GBS surface. Both N- and C-terminal stretches of the Alps possess immunogenic sites of dissimilar immunological specificity. In this review, we have compiled data dealing with the specificity of the N- and C-terminal immunogenic sites of the Alps. The majority of N-terminal sites show protein specificity while the C-terminal sites show broader cross-reactivity. Molecular serotyping has revealed that antibody-based serotyping has often resulted in erroneous Alp identification, due to persistence of cross-reacting antibodies in antisera for serotyping. Retrospectively, this could be expected on the basis of sequence analysis results. Some of the historical R proteins are in fact Alps. The data included in the review may provide a basis for decisions regarding techniques for the preparation of specific antisera for serotyping of GBS, for use in other approaches in GBS research, and for decision making in the context of GBS vaccine developments.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25540270      PMCID: PMC4308872          DOI: 10.1128/CVI.00643-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  58 in total

1.  Identification of a glycosaminoglycan binding region of the alpha C protein that mediates entry of group B Streptococci into host cells.

Authors:  Miriam J Baron; David J Filman; Gina A Prophete; James M Hogle; Lawrence C Madoff
Journal:  J Biol Chem       Date:  2007-01-26       Impact factor: 5.157

2.  Variation in repeat number within the alpha C protein of group B streptococci alters antigenicity and protective epitopes.

Authors:  C Gravekamp; D S Horensky; J L Michel; L C Madoff
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

3.  A Streptococcus agalactiae R protein analysed by polyclonal and monoclonal antibodies.

Authors:  L Bevanger; A I Kvam; J A Maeland
Journal:  APMIS       Date:  1995-10       Impact factor: 3.205

4.  Distribution of serotypes and antimicrobial resistance genes among Streptococcus agalactiae isolates from bovine and human hosts.

Authors:  Belgin Dogan; Y H Schukken; C Santisteban; Kathryn J Boor
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

5.  Immunogenicity and protective efficacy of the alpha C protein of group B streptococci are inversely related to the number of repeats.

Authors:  C Gravekamp; D L Kasper; J L Michel; D E Kling; V Carey; L C Madoff
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

6.  Characterization of two distinct opsonic and protective epitopes within the alpha C protein of the group B Streptococcus.

Authors:  D E Kling; C Gravekamp; L C Madoff; J L Michel
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

7.  Neonatal group B streptococcal infection in Mallorca, Spain.

Authors:  J A Hervás; L González; J Gil; L C Paoletti; L C Madoff; V J Benedí
Journal:  Clin Infect Dis       Date:  1993-05       Impact factor: 9.079

8.  Type-specific antigens of group B type Ic streptococci.

Authors:  H W Wilkinson; R G Eagon
Journal:  Infect Immun       Date:  1971-11       Impact factor: 3.441

9.  Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease.

Authors:  Philippe Glaser; Christophe Rusniok; Carmen Buchrieser; Fabien Chevalier; Lionel Frangeul; Tarek Msadek; Mohamed Zouine; Elisabeth Couvé; Lila Lalioui; Claire Poyart; Patrick Trieu-Cuot; Frank Kunst
Journal:  Mol Microbiol       Date:  2002-09       Impact factor: 3.501

10.  Serotype III Streptococcus agalactiae from bovine milk and human neonatal infections.

Authors:  John F Bohnsack; April A Whiting; Gabriela Martinez; Nicola Jones; Elisabeth E Adderson; Shauna Detrick; Anne J Blaschke-Bonkowsky; Naiel Bisharat; Marcelo Gottschalk
Journal:  Emerg Infect Dis       Date:  2004-08       Impact factor: 6.883

View more
  14 in total

1.  Population structure and virulence gene profiles of Streptococcus agalactiae collected from different hosts worldwide.

Authors:  Marina Morach; Roger Stephan; Sarah Schmitt; Christa Ewers; Michael Zschöck; Julian Reyes-Velez; Urs Gilli; María Del Pilar Crespo-Ortiz; Margaret Crumlish; Revathi Gunturu; Claudia A Daubenberger; Margaret Ip; Walter Regli; Sophia Johler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-11-27       Impact factor: 3.267

2.  C-protein α-antigen modulates the lantibiotic thusin resistance in Streptococcus agalactiae.

Authors:  Nemanja Mirkovic; Mina Obradovic; Paula M O'Connor; Brankica Filipic; Branko Jovcic; Paul D Cotter; Milan Kojic
Journal:  Antonie Van Leeuwenhoek       Date:  2021-07-28       Impact factor: 2.271

3.  Identifying large-scale recombination and capsular switching events in Streptococcus agalactiae strains causing disease in adults in the UK between 2014 and 2015.

Authors:  Uzma Basit Khan; Elita Jauneikaite; Robert Andrews; Victoria J Chalker; Owen B Spiller
Journal:  Microb Genom       Date:  2022-03

4.  Serotype IV Streptococcus agalactiae ST-452 has arisen from large genomic recombination events between CC23 and the hypervirulent CC17 lineages.

Authors:  Edmondo Campisi; C Daniela Rinaudo; Claudio Donati; Mara Barucco; Giulia Torricelli; Morven S Edwards; Carol J Baker; Imma Margarit; Roberto Rosini
Journal:  Sci Rep       Date:  2016-07-14       Impact factor: 4.379

Review 5.  Streptococcus agalactiae Non-Pilus, Cell Wall-Anchored Proteins: Involvement in Colonization and Pathogenesis and Potential as Vaccine Candidates.

Authors:  Giampiero Pietrocola; Carla Renata Arciola; Simonetta Rindi; Lucio Montanaro; Pietro Speziale
Journal:  Front Immunol       Date:  2018-04-05       Impact factor: 7.561

Review 6.  A Vaccine Against Group B Streptococcus: Recent Advances.

Authors:  Clara Carreras-Abad; Laxmee Ramkhelawon; Paul T Heath; Kirsty Le Doare
Journal:  Infect Drug Resist       Date:  2020-04-29       Impact factor: 4.003

7.  Defining the remarkable structural malleability of a bacterial surface protein Rib domain implicated in infection.

Authors:  Fiona Whelan; Aleix Lafita; Samuel C Griffiths; Rachael E M Cooper; Jean L Whittingham; Johan P Turkenburg; Iain W Manfield; Alexander N St John; Emanuele Paci; Alex Bateman; Jennifer R Potts
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-09       Impact factor: 11.205

8.  Multistate, Population-Based Distributions of Candidate Vaccine Targets, Clonal Complexes, and Resistance Features of Invasive Group B Streptococci Within the United States, 2015-2017.

Authors:  Lesley McGee; Sopio Chochua; Zhongya Li; Saundra Mathis; Joy Rivers; Benjamin Metcalf; Alison Ryan; Nisha Alden; Monica M Farley; Lee H Harrison; Paula Snippes Vagnone; Ruth Lynfield; Chad Smelser; Alison Muse; Ann R Thomas; Stephanie Schrag; Bernard W Beall
Journal:  Clin Infect Dis       Date:  2021-03-15       Impact factor: 9.079

9.  High-resolution profiling of linear B-cell epitopes from mucin-associated surface proteins (MASPs) of Trypanosoma cruzi during human infections.

Authors:  Ignacio M Durante; Pablo E La Spina; Santiago J Carmona; Fernán Agüero; Carlos A Buscaglia
Journal:  PLoS Negl Trop Dis       Date:  2017-09-29

10.  Progress toward a group B streptococcal vaccine.

Authors:  Joon Young Song; Jae Hyang Lim; Sangyong Lim; Zhi Yong; Ho Seong Seo
Journal:  Hum Vaccin Immunother       Date:  2018-07-16       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.